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A B S T R A C T
In this article, the theoretical foundation for salts is given with an emphasis on the amount
of drug in solution. Consideration is given for the solubility of the non-ionized form, acid
dissociation constant and solubility product, which are the limiting constraints. For disso-
lution of nonionized drugs, the surface pH differs from the bulk pH, giving rise to a lower
than expected rate. For salts, theoretical considerations are relatively complex, and an ex-
perimental approach to estimating the surface pH is more likely to be of value in predicting
the dissolution rate. General guidelines are described for screening, preparing and charac-
terizing drugs as salts, which critically depend on the goal of the product development.
Thereafter, our work involving the preparation of salts as a means to generate aerosols from
a solution is provided. The solubility of six structurally related compounds was determined
in four acids.Thereafter, the amount of the compound in solution was determined as a func-
tion of pH, using the acid that provided the highest solubility. Because the pH required to
achieve the needed concentration for aerosol generation was low, ammonia vapor was in-
troduced into the air stream to neutralize aerosol droplets. Solvent was then removed from
the aerosol by a silica column. The resulting aerosol had a concentration of 96 μg/l and a
mass median particle size of 1.8 μm.The reported pharmacokinetic study substantiated the
feasibility of evaluating its safety and efficacy of inhalation administration in the rat model.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
1.1. Prevalence and importance of salts
The formation of salts is invaluable for the preparation of safe
and effective dosage forms of many drugs [1–3]. Whether the
drug products are solutions or solids, the use of a salt pro-
vides a higher concentration in solution than the free acid or
free base (nonionized forms). Typically, salts readily undergo
crystallization, and the resulting material facilitates subse-
quent processing. Thus, the salt is often the preferred form for
isolating and purifying the drug. Historically, the number of
available salts was rather limited; however, today there is a wide
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range of chemical entities that are recognized as being safe,
which can be used in the preparation of drug products (cf
Table 1) [4,5].
In addition to solubility and manufacturing, the salt is typi-
cally a more stable form of the drug. This too is an important
advantage for developing a product with a long shelf-life. Al-
though non-ionized drugs often exist in multiple polymorphic
forms, the number for salts appears limited. This may be an
inherent property of the ionic bond, but it should also be rec-
ognized that relatively little effort has been expended in the
search for different polymorphic forms of salts [6]. As such, there
may be an untapped potential, because as it has been noted,
the number of polymorphic forms appears to be function of
the time expended in searching for them.
In this article, the theoretical foundation for salts is given
with an emphasis on the observed increased amount of drug
in solution. Here, consideration is given for the solubility of the
non-ionized form, acid dissociation constant and solubility
product, which are the limiting constraints. The salient fea-
tures of the pH dependence of the dissolution of nonionized
and ionized drugs and their salts are given. Some general guide-
lines are reviewed for screening and characterizing drugs as
salts for development of products. Thereafter, our work in-
volving the preparation of salts as a means to generate aerosols
from a solution is provided. Here, in situ neutralization was
needed to allow the drug to be evaluated for safety and effi-
cacy in a rat model of a respiratory disease.
1.2. Definitions
In 1923, Johannes Nicolaus Brønsted (Denmark) and indepen-
dently Martin Lowry (England) formulated a definition of an
acid and a base [7]; an acid (generically HA) gives up or donates
a proton (hydrogen ion, H+) and a base (B) accepts a proton.
This may be written as:
Acid HA H A:  + −+
Base B H BH: + + +
It can be noted that A− acts as a base in the reverse reac-
tion and is thus called a conjugate base, just as BH+ acts as an
acid and is referred to as a conjugate acid. These form a con-
jugate acid–base pair. That is:
Acid Base H + +
Water is amphoteric, acting as both an acid and a base, and
is often the source of the hydrogen ions as well as hydroxide
ions in pharmaceutical systems. The Brønsted–Lowry model
explains the dissociation of water into hydronium and hy-
droxide ions:
H O H O H O OH2 2 3+ ++ −
This is a type of disproportionation reaction, in which iden-
tical components react to form two different species. The
corresponding equilibrium constants follow the usual con-
vention and are as follows with the assumption of ideality:
Acid dissociation constant K H A HAa, = [ ][ ] [ ]+ −
Base dissociation constant K BH OH Bb, = [ ][ ] [ ]+ −
For water,
K H OHw = [ ][ ]+ −
In these expressions, the concentration of water is assumed
constant and incorporated into Kw, Ka, and Kb. Finally, for a given
conjugate acid–base pair, it is noted that:
Table 1 – List of compounds available for preparing salts [4].
Cations Anions
Aluminum Acetate Glutamate Mucate
Arginine Aspartate Glycolate Napsylate
Benzathine Benzenesulfonate Glycollylarsanilate Nitrate
Calcium Benzoate Hexanoate Octanoate
Chloroprocaine Besylate Hexylresorcinate Oleate
Choline Bicarbonate Hydrabamine Pamoate
Diethanolamine Bitartrate Hydroxynaphthoate Pantothenate
Ethanolamine Bromide Iodide Phosphate
Ethylenediamine Camsylate Isethionate Polygalacturonate
Histidine Carbonate Isethionate Propionate
Lithium Chloride Lactate Salicylate
Lysine Citrate Lactobionate Stearate
Magnesium Decanoate Malate Subacetate
Meglumine Edetate Maleate Succinate
Potassium Estolate Mandelate Sulfate
Procaine Esylate Mesylate Tartrate
Sodium Fumarate Methylbromide Teoclate
Triethylamine Gluceptate Methylnitrate Tosylate
Zinc Gluconate Methylsulfate Triethiodide
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K K Kw a b=
and introducing the convention that the operator, p(x) = − log(x),
then
pK pK pKw a b= +
The value of pKw is 14.00 at 25 °C, while the value of the
acid dissociation constant of a weak acid or conjugate acid of
a weak base is governed by the chemical interaction between
the solute and the solvent [8].
A salt is an ionic compound that results from a reaction of
an acid and a base. In general, this is written as:
mB nA B A sn m m n+ −+ ( )
where m moles of the base with a valence of n+ combine with
n moles of an acid of valence m− to form a solid (s) salt with
the given stoichiometry to achieve electro-neutrality.
1.3. Solubility and solubility product
The thermodynamic definition of a solution is a mixture of two
or more substances, which forms a stable, molecular disper-
sion [8].The process of solution involves a change in the system
from an initial state comprising a solid and a pure liquid phase
and the final state comprising a drug in solution.The change in
Gibbs free energy is related to the amount of solute in solution.
The solubility is the maximum amount of material (e.g. solid)
that will dissolve in a given volume of solvent. This is an equi-
librium property, and there are no degrees of freedom with
specifying the two components (solute and solvent) and the tem-
perature and pressure. For equilibrium to exist, the solid form
of the solute must be in the lowest energy state.As is well known,
solids often have multiple polymorphic forms, which exist in
higher energy, metastable states or can incorporate water (hy-
drates) or other solvents (solvates) into the crystalline lattice.
In addition, a solid need not have a crystalline structure but can
exist in an amorphous form. In this discussion, these aspects
will not be considered as they have been recently reviewed [6].
The solubility of a salt is more complicated, because disso-
ciation introduces another component and thereby an additional
degree of freedom [1].Here, the definition of the solubility product,
Ksp, stems from the chemical equation used for the salt:
K B Asp n
m m n
= [ ] [ ]+ −
where the solid salt is taken as having unit activity. For a con-
crete example, ephedrine can be used, where 25 different salts
were made [9]. The solubility product of the HCl salt is written
as follows:
K Ephedrine-H Clsp = [ ][ ]+ −
In essence, there are now three components: ephedrine,
chloride, and the solvent, water.As Ksp is a constant, the amount
of ephedrine in solution depends on the concentration of chlo-
ride ions.
For the other salt forms, each will have a unique solubility
product that determines the amount of ephedrine in solution
along with the concentration of the counter ions. Moreover in
solution, ephedrine must necessarily exist both as a base and
conjugate acid; the distribution is governed by the acid dis-
sociation constant and the pH of the solution. Thus, along with
specifying the temperature and pressure, the additional pa-
rameters of the pH, [Cl−], and pKa must be defined to ascribe
a unique value for the maximum amount of ephedrine in so-
lution. A cautionary note is in order as often an apparent
solubility product is reported. That is, rather than determining
the concentration of the ionized form, the total concentration
is determined [10]. This apparent solubility product, Ksp,app, is
given by
K C counter ionsp app tot, = [ ][ ]
Weak acid K HA A Msp app, , = + [ ]{ }[ ][ ] − +
Weak base K B BH Xsp app, , = + [ ]{ }[ ][ ] + −
Perhaps the most dramatic example of the influence of the
solubility product on the total amount of drug in solution is
chlorhexidine (CHX) [11,12]. Three possible salt forms are the
dihydrochloride, diacetate, and digluconate. The correspond-
ing solubility products yield CHX concentrations in the ug/ml,
mg/ml, and the gluconate readily forms a 40 wt% solution.The
latter observation has been related to the self-association of CHX
in the presence of gluconate ions.This represents another pos-
sibility with additional theoretical implications. That is,
CHX-gluconate CHX gluconate2 2 2 + −+
CHX CHX CHX2 2 2
2
+ + ++ ( )
CHX CHX CHX2
2
2 2
3
+ + +( ) ( )+ 
…
where the stepwise self-association may be described by mul-
tiple equilibria.
1.4. Ion pairing
A related phenomenon is when the salt is dissolved but does
not undergo complete dissociation. When the counter ion
remains spatially close to the parent compound, the associa-
tion is written chemically as:
B A s B Am n mn nm aq( ) ( )+ −
Bjerrum [8] initially suggested that the term, ion pair, be used
to describe two ions that have a separation distance less than
q, which is given by:
q
z z e
kT
i j
o r
=
2
8π εε
where z is the valence, e is the electronic charge, εo is the per-
mittivity of a vacuum, εr is the relative permittivity of the
solution, and kT is the thermal energy given by the product
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of Boltzmann’s constant and the temperature in Kelvin. In
essence, this equation provides the distance at which the
Columbic attractive energy is equal to the thermal energy.
1.5. Complexation
The word complex is used in a number of pharmaceutical con-
texts. Complexation is defined as the reversible, non-covalent
interaction between m molecules of a drug with n molecules
of a ligand species. Generally, it refers to a type of binding that
involves strong attractive intermolecular interactions or equiva-
lently, high affinity, and therefore has a large association
constant. In chemistry, it typically refers to association with
metals, although IUPAC recommends the term, coordination
entity [8]. This involves a metal center plus ligands. Com-
plexes can be positively charged, neutral, or negatively charged.
The overall charge on the complex depends on the oxidation
state of the metal and the charges brought by the ligands. The
ligand may have a single bond or single coordination number
(unidentate = literally, one tooth) or multiple bonds (multiple
coordination number or multidentate). In the latter case, the
term chelate (claw) is used, which implies encirclement of the
metal ion by the ligand. Ethylenediamine tetraacetic acid (EDTA)
with metal ions is the well-known pharmaceutical example
of a coordination entity.
1.6. pH-solubility
The primary purpose of forming a salt is to increase the amount
of drug in solution [1–3]. Because the vast majority of ap-
proved drugs are weak acids or bases, the latter of which is
much more common, it is instructive to address the pH de-
pendence of the amount of drug in solution. The usual
assumptions are that the ionized form has an infinite solu-
bility and the solubility of the non-ionized form, Cs, is
independent of pH. This allows derivation of the following ex-
pressions for the total amount of drug in solution, Ctot [2,13,14]:
Weak acid C Ctot s pH pKa: = +[ ]−( )1 10
Weak base C Ctot s pKa pH: = +[ ]−( )1 10
In Fig. 1, the curved lines are given for the theoretical plot
of the total concentration of a weak base and weak acid, both
with a pKa of 5. The total concentration rises with a decrease
in pH for the weak base, whereas it rises with an increase in
pH for the weak acid.
Despite the assumption, the solubility of the ionized form
cannot be infinite as it is constrained by the solubility product.
Thus, an observed maximum solubility at a specified pH, that
is, pHmax, is predicted [2]. In the case when HA forms a salt of
M+A−, the solubility product is:
K M A Asp = =[ ][ ] [ ]+ − − 2
assuming the only source of the cation arises from the salt.
The total amount in solution is then given by:
C HA K H K Ktot sp a sp= + = +[ ] [ ]( )+1 2 1 21
The corresponding equation for a weak base is:
C B K K H Ktot sp a sp= + = +[ ] [ ]( )+1 2 1 21
These are shown as horizontal dotted lines in Fig. 1, which
are independent of pH when the amount in solution is deter-
mined by the solubility product of the salt.This may be observed
by preparing the salt as a saturated solution and controlling
the pH with a buffer that neither contains the counter ion in
the salt nor appreciably affects the observed amount of salt
in solution.
A more common approach to measure the solubility as a
function of pH is to place excess nonionized form into the
solvent and vary the amount of acid, HX, (or base, MOH) to yield
a range of pH values [2]. Chemically, this is given as:
HA MOH M A H O+ + ++ − 2
B HX BH X+ ++ −
The observed total amount of drug in solution plotted as
a function of pH will increase, reach a maximum, and then de-
crease. The decrease arises from the solubility product, which
is also shown in Fig. 1 as straight lines, decreasing in the op-
posite direction to the effect of ionization. That is, the addition
of an acid (or base) must necessarily involve the addition of
counter ions, M+ (or X−), which causes the drug concentration
to fall in proportion to the added counter ion. This is known
as the common ion effect.
Thus, there are the two relationships for the total amount
of weak acid in solution; one constrained by the pKa at low pH
and the other by the Ksp at high pH. The intersection of the
two relationships yields the maximum possible total concen-
tration. Equating these expressions and solving for [H+]max yields
the pH at which this occurs, pHmax [2],
Weak acid: [H+]max = Ka[HA]o/Ksp1/2
pHmax = pKa + 0.5pKsp − log[HA]
Weak base: [H+]max = KaKsp1/2/[B]
pHmax = pKa − 0.5pKsp + log[B]o
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Fig. 1 – Total concentration of weak acid and weak base in
solution as a function of pH reflecting the effect of
ionization and solubility product.
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where [HA]o and [B]o represent the solubilities of the nonionized
forms of the weak acid and weak base, respectively. In these
expressions, the maximum in the amount of drug in solution
will be displaced from the pKa by the value of the pKsp and
solubility of the nonionized from. That is, for a weak acid the
pHmax is moved to a value greater than the pKa as pKsp becomes
larger. For a weak base, an analogous shift is seen, but here it
is to a lower value of the pKa. pKsp appears as the square root
due to the assumption that the counter ion concentration is
equal to the concentration of the ionized form; Ksp = [A−]2 or
[BH+]2. The solubility of the nonionized form, either [HA] or [B],
offsets the effect of pKsp and shifts the pHmax closer to the pKa.
1.7. Nonionized drug dissolution
The use of salts to generate a drug with high water solubility
may represent the end goal for preparation of a solution for-
mulation. However, it is much more commonly exploited in solid
dosage forms, where the goal is to yield a drug product with
a high dissolution rate [2,13–16]. The value in having a high
dissolution rate is that dissolution and the subsequent mem-
brane transport can be completed in the allotted gastrointestinal
transit time.
The Noyes–Whitney equation provides the empirical rela-
tionship for the rate of dissolution, dm/dt, and is given as [1]:
dm dt DS h C Cs b= −( )( )
where D is the diffusion coefficient, S is the surface area, Cs
and Cb are the concentrations at the surface and the bulk, re-
spectively. The parameter, h, is the diffusional boundary layer
thickness (DBL) or sometimes referred to as the unstirred or
stagnant layer. The DBL appears to be the distance over which
diffusion occurs but in reality involves both diffusive and con-
vective contributions [13,17]. Moreover, these contributions
vary with the distance from the solid surface. This is shown
in Fig. 2.
An exact, analytical expression for dissolution, which sepa-
rates the diffusive and convective contributions, is available
provided the contribution from convection is controlled. The
rotating disk method is an example for which the equation for
the DBL was derived by Levich [18] and is:
h D= −1 61 1 3 1 6 1 2. ν ω
where ν is the kinematic viscosity and ω is the angular veloc-
ity (rad/s). With the use of a dissolution apparatus (e.g. USP
Dissolution Apparatus I or II), the hydrodynamic conditions are
reproducibly controlled but do not afford an analytical solu-
tion for the DBL.
1.8. Dissolution of weak acids and bases
The above expression is appropriate for the dissolution of a
free acid or base, when ionization can be neglected. For dis-
solution of a species in which ionization occurs, the situation
is more complicated as there is more than one component un-
dergoing diffusion [2,13,15–17]. At the interface, HA (or B) will
undergo ionization to form A− (or BH+), the distribution is de-
termined by the pKa and pH. If the assumption is initially made
that the pH is uniform and the diffusion coefficients of the
ionized and nonionized forms are the same, then the rate of
dissolution should increase in proportion to the increase in the
ionized concentration. However, due to the dissociation, the
interfacial pH for the weak acid will be lower than the bulk.
For the base, the interfacial pH will be higher as OH− is formed
with ionization of B to BH+. The difference in pH between the
interface and bulk will be a function of the relative transport
rates of the drug away from the surface and the diffusion of
H+ and drug solubility. Moreover, despite the relatively rapid
diffusion of protons in water, the pH difference can be significant.
Mooney et al. [13,15] performed the seminal work involv-
ing the dissolution of benzoic acid as a function of pH in
unbuffered solutions. In excellent agreement with theoreti-
cal predictions, the surface pH was similar to the bulk pH at
low pH values where little dissociation took place. However,
as the bulk pH was raised through the pKa, the surface pH was
found to be much lower than the bulk, a result of the self-
buffering capacity of benzoic acid.That is, benzoic acid dissolves
in water and dissociates into the benzoate anion and a proton.
The proton will diffuse away from the surface, but the time
dependence of this transport step maintains the pH at the solid
interface at a lower value than the bulk. Fig. 3A shows the
surface pH as a function of bulk pH for four different weak acids
that vary with respect to pKa.This self-buffering affects the flux
as shown in Fig. 3B, which reveals a similar plateau in the data
indicating a lower than expected flux given the high bulk pH.
Studies were also conducted with naphthoic acid [15]. Here,
there was also a buffering effect, but it was smaller. This can
be understood by the lower solubility of naphthoic acid and
hence the slower dissolution rate, which will result in a smaller
rate of production of protons for maintaining a low pH at the
surface. At much higher pH values, this effect was dimin-
ished, but the surface pH still remained lower than the bulk
pH by more than six units. The effect of the intrinsic solubil-
ity on the surface pH is shown in Fig. 3C. The surface pH is
seen to be lower as the solubility of the weak acid is in-
creased, due to the greater release of protons. A more general
equation was derived by McNamarra and Amidon [17], which
followed the approach of Levich. This is more rigorous but also
more cumbersome for calculations.
1.9. Dissolution of salts
In Fig. 4A and B, schematic diagrams are given for the disso-
lution of a salt of weak acid, MA, and a salt of weak base, BHX
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lid
Fig. 2 – Schematic diagram of dissolution of drug depicting
actual concentration (solid line) and assumption of
linearity (dotted line).
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[10,19]. The acid–base reactions of the drugs at the surface are
further complicated by the presence of the counter ions, M+
and X−. For the simple case, when the bulk pH is set to a value
where the drugs are largely present in the ionized form, the
dissolution rate is proportional to the concentration of the
ionized form, A− or BH+, as given by the Ksp. For pH values that
approach the pKa, MA (or BHX) will dissolve and undergo dis-
sociation into M+ and A− (or BH+ + X−), generally assumed to be
complete. HA will form in the presence of H+ in the solution
(and BH+ formed with water); the extent is determined by the
pKa and the pH at the interface. That is:
MA M A K M Asp + − + −+ = [ ][ ];
A H O HA OH K HA OH Ab− − − −+ + = [ ][ ] [ ]2  ;
The equilibrium values, pH, log[HA], and log[A−] are shown
as a function of log(Ksp) in Fig. 5 for a weak acid with a pKa of
7.0. It can be seen that as the Ksp increases from 10−14 to 10−4
or ten orders of magnitude, [A−] increases five orders of mag-
nitude as [A−] = Ksp1/2. The pH increases from just below 7 to
near 9.5 in a similar manner as [HA], which increases from 10−7
to 10−4.5.
For dissolution of a salt at pH values where acid–base re-
actions will occur, there is simultaneous transport of both forms
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Fig. 3 – (A) Surface pH as a function of bulk pH for solutes with different pKa’s, (B) flux arising from dissolution as a
function of bulk pH for drugs with different pKa’s, and (C) surface pH as a function of bulk pH for drugs with different
intrinsic solubilities.
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of the drug, HA and A− (and B and BH+) from the surface
[10,16,19]. In addition, OH− will diffuse into the bulk. However,
in these cases, the drug counter ion, M+ or X−, is present, which
too is transported away from the surface due to its high in-
terfacial concentration.The presence of the counter ions affects
the transport of H+, and therefore the pH at the interface (mi-
croenvironment pH) as well.
At this point, it is of value to comment about the relative
diffusion rates of H+ and OH−. Because of the extensive hydro-
gen bonding and rapid exchange of protons among water
molecules, there is not typically physical movement of a proton,
but rather a formation and associated cleavage of the O—H bond
in the neighboring water molecules as shown in Fig. 6 [20].This
is known as the Grotthuss mechanism, where proton-hopping
occurs among the main forms of solvated hydrogen ions of H9O4+
(Eigen cation) and H5O2+ (Zundel cation). It can also be appre-
ciated that proton movement in a specified direction necessary
involves OH− movement in the opposite direction, and thus the
equal diffusivities of H+ and OH− become unremarkable.
Returning to the consideration of the dissolution rate of a
salt, the key experimental parameter in determining the rate
is the interfacial pH as this determines the extent of dissolu-
tion. Rather than use a theoretical calculation of the interfacial
pH, Serradajin et al. [10,19] developed an experimental ap-
proach. Excess salt was dispersed into water, and the pH of
the solution was determined, which was argued to be repre-
sentative of the interfacial pH. They found that the rate of
dissolution correlated much better with the total concentra-
tion of solute using the measured pH in comparison to the bulk
pH. In examining the equations, the initial concentration of
the salt will be determined by the solubility product,
K A M Asp = =[ ][ ] [ ]− + − 2
However, A− will react with water to form HA. This has two
effects: one, the pH will be increased by the formation of OH−,
and two, additional MA will go into solution to raise the con-
centration such that the Ksp is satisfied. When this occurs,
[A−] < [M+], because A− was consumed in the formation of HA.
The governing equation becomes
K A HA x M xsp o= − + +[ ] [ ]( ) ∗ [ ]( )− +
where x represents the additional concentration of salt that
will dissolve to satisfy the solubility product, and
K H A HAa = [ ][ ] [ ]+ −
Intuitively, as the pH difference between the interface and
bulk becomes larger, there is a favorable effect on the extent
of ionization. Thus, the total concentration is higher than ex-
pected based on bulk pH calculations, and thereby the
dissolution rate is also higher.
The above analysis considered only conditions where the
species remained in solution despite being unstable. In con-
ducting dissolution experiments, metastable solutions can
undergo conversion to the more stable state, characterized
by precipitation [1,2,10,21,22]. This is analogous to the disso-
lution experiments conducted with a metastable polymorphic
form or amorphous form of a nonionized drug. With the
dissolution of salts, the precipitated solid may be composed
of the nonionized form of the drug or the salt, depending on
the pH. The location of the precipitation is also variable,
because it can occur in the bulk solution or at the surface of
the solid, again depending of the pH (dictating the degree of
supersaturation) and nucleation tendency. There are a number
of examples cited in the literature, which were explained
according to appropriate theoretical considerations [2,22].
However, the complexity of the dissolution process in regard
to the distant dependent pH coupled with the difficulty in
predicting nucleation and crystal growth of solids makes a
priori prediction of what will precipitate (free acid or base, or
salt) and where it will precipitate (bulk or surface) intrac-
table. In essence, experimentation is required to ascertain
the outcome.
1.10. Salt screening for conventional dosage forms
The complexity of the dissolution of salts and its depen-
dence on pH poses a dilemma for the drug development process
but also creates opportunities. That is, for the dilemma, de-
velopment of a new chemical entity into a marketable drug
product requires extensive experimentation, even if just limited
to salt selection [23–27]. The opportunity arises from the fact
that the experimental parameter space is large; too large to
be exhaustively examined in the initial commercialization.Thus,
following marketing, it is not only possible but perhaps prob-
able, that a new drug product can be developed, which
comprises a different salt or polymorphic form and also has
superior performance in terms of dissolution rate or chemi-
cal stability. In this section, the general approach to screening
NCEs for salt selection is provided along with the factors to
be considered and the methods of characterization.
For the development of dosage forms, the physical state of
the active ingredient has a critical role in the observed per-
formance [23,24,28–33]. The first consideration is the dosage
form, for which there are many possibilities [4,6]. Thereafter,
solubility, chemical stability, degree of crystallinity, and the me-
chanical properties are important factors. Limiting the
discussion to drugs that must be in solution or solid state, the
solubility is critical. For liquids, an adequate amount of drug
must be in solution so that the entire dose is contained in a
reasonable volume for convenient dosing, with preference often
for a smaller volume. For drugs in the solid state, as present
in tablets and capsules, the solubility is also important, because
Fig. 6 – Grotthuss mechanism of hydrogen ion and
hydroxide ion diffusion.
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this in turn has a profound effect on the dissolution rate, which
can affect the rate and extent of absorption.
Another critical property is stability. Here, there is an obvious
preference to prepare a very stable dosage form. Even though
solubility may be the end goal, the significance of stability is
such that it should be the first criterion used in selecting the
form of the drug. Related to stability is the purity and unifor-
mity of the material. For example, preference is given to those
compounds that readily form highly crystalline solids and can
be prepared easily and economically. In the development of
solid dosage forms, the interaction of the drug with water,
whether it is the hygroscopicity or deliquescence behavior, is
of concern. Also specific for solid drugs are the mechanical prop-
erties. Although a listing of the important properties for tableting
is beyond the scope of this overview, the reader can readily ap-
preciate that the ease in consolidating and compressing drug
particles with excipients into a functional tablet will often
depend on the crystal structure of the drug.
The above properties are well-recognized, but presently there
are no reliable methods to guide the formulation scientist in
selecting or even preparing the form of the drug that will best
meet the criteria. In fact, most often, no one drug form best
meets all of the criteria. Thus, devoid of theoretical predic-
tion, it remains a process of screening to identify the optimal
form among competing interests. At the outset, there must be
a clear goal for the screening process. The initial screen for an
NCE is carried out often with little material available, and the
goal is to determine the propensity for polymorphism. When
more material becomes available, additional screening is carried
out to identify the stable form. Thereafter, confirmation is
needed that the selected form can be prepared with GMP ma-
terial and then identify the best form for product development.
Lastly, an extensive screen can be conducted in an attempt to
identify all possible forms. The purpose here is to have ex-
pansive patent protection. Alternatively, screening may also be
conducted with a drug that is in a marketed product. Here, the
goal is to identify a form that has superior properties and pos-
sibly can be considered new intellectual property.
The screening process begins with selecting possible counter-
ions to prepare the salts [23–25,30,32,33]. Table 1 was provided
in the context that there is a benefit from the wide range of
possibilities, but in the context of screening, it represents an
extremely large experimental space. It is unrealistic to screen
all possible counter ions in the preparation of salts, and for-
tunately, there are some broad guidelines to limit the selection.
It goes without saying that a negatively charged counter ion
is needed for a drug that is a weak base and positively charged
counter is needed for a weak acid. The second guideline is that
the drug must be completely ionized and in a single state of
ionization in order to allow salt formation. With incomplete
ionization, there is a risk of precipitating the nonionized form;
and with multiple ionization states, there is a risk of forming
a mixture of salts. The third limiting guideline is that the pKa
of the base and the acid should differ minimally by a factor
of two, although there are exceptions, where the difference is
less. It should also be noted that the pKa difference must be
maintained in the solvent system used for crystallization. The
point here is that often non-aqueous or mixed solvent systems
are used in the crystallization, which can dramatically affect
the observed pKa.
1.11. Preparation methods of salts
With identification of the counter ions that will be used, the
next task is to select the methods for preparing salts
[25–27,34–36].There are four main methods used for salt prepa-
ration: thermal, anti-solvent, evaporation, and slurry conversion.
In each of these methods, the outcome is dependent on several
experimental variables, given below; however, all methods will
be sensitive to the additive type and concentration, pH, and
ionic strength. Moreover, the goal here is not to identify the
process for salt preparation but to obtain seed crystals that can
be subjected to preliminary evaluation.
The thermal method exploits the temperature depen-
dence of the solubility, where a solution is prepared at a high
temperature that is then cooled to cause precipitation. The
outcome can depend on the heating rate, cooling rate,
maximum temperature, and incubation temperature and time.
The anti-solvent approach involves the addition of a solvent
to a solution that induces precipitation, because of the lower
solubility. Here, it is helpful to be aware of the dielectric con-
stant of each of the solvents to limit the possibilities. In addition,
the yield of precipitated material can depend on the anti-
solvent and the rate at which it is added and the temperature
and time of the addition. Evaporation relies on the selective
removal of the solvent to increase the solution concentration
to the point where the solubility is exceeded resulting in pre-
cipitation. The important processing parameters are the rate
and time of evaporation, carrier gas, and the surface to volume
ratio of the solution container. Finally, slurry conversion in-
volves a solvent mediated polymorphic transition from a
metastable solid form through a supersaturated solution and
ultimately formation of a stable solid form. It is sensitive to
mixing rate, impeller and crystallization vessel design, and the
solvent.
Other less common methods include the use of capillary
crystallization, binary melts, grinding, salt exchange, vapor dif-
fusion or bubbling (volatile acids or bases; e.g. HCl, ammonia),
ion exchange resins, varying pH as in a phase solubility study,
and selective precipitation of unwanted counter ion (e.g. use
of silver salts, where the unwanted silver is removed as silver
iodide) [24,35]. The traditional approach of preparing indi-
vidual samples has given way to high throughput screens that
are conducted in 96-well plates [26]. This allows preparation
of a large number of samples, but tends to be limited to solvent
based methods with fewer conditions allowed for crystallization.
1.12. Characterization methods for salts
With material in hand, the next step is to characterize the
samples [4,6,24,28,30,32]. X-ray powder diffraction is the de-
finitive tool for characterizing crystalline samples. The pattern
observed is unique to the polymorphic form and allows veri-
fication that the material is crystalline, as amorphous samples
will yield a featureless halo. The appearance of the peaks also
provides information on the uniformity, where broadened peaks
indicate a lack of crystallinity, provided the particle size is suf-
ficiently large. Complementary spectroscopic methods are
infrared (IR), Raman, and nuclear magnetic resonance (NMR).
IR and Raman spectroscopy are most readily available and can
be used to assess interactions in the solid state, particularly
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between the parent compound and the counter ion. NMR spec-
troscopy, particularly solid state, is much more cumbersome
to use and typically requires >10–50 mg for a sample. It can
be quantitative, but usually requires an experienced indi-
vidual to avoid pitfalls.
Thermal methods, including differential scanning calorim-
etry (DSC), thermogravimetry (TG), and hot stage microscopy,
are readily available, easy to perform, and do not require a large
sample size. DSC can be used to determine the melting point
and enthalpy of fusion. Neither are specifically required prop-
erties, but they are extremely helpful in predicting solubility
and stability.The sharpness of the melting endotherm also gives
an indication of the purity and crystallinity of the sample.
Complex thermograms reveal polymorphism, which can be in-
dispensable in the search for the most stable form. Finally,
hydrates and solvates can generally be distinguished from an-
hydrous forms due to the nature of the endotherm associated
with their loss of volatile components from the sample.TG pro-
vides a measure of the weight change either at a constant
temperature or as a function of the changing temperature. As
such, it can provide information as to the amount of ad-
sorbed moisture for hygroscopic samples as well as the
stoichiometry of hydrates/solvates. Hot stage microscopy pro-
vides visual evidence to confirm the nature of the thermal
changes, whether it be melting, phase change, or decomposi-
tion. Other routine characterization based on microscopy would
be visual characterization of the particle size and morphology.
1.13. Inhalation formulation
Our objective was to develop an inhalation formulation of a
drug from several possible candidates to evaluate the safety
and efficacy in a rat animal model [36]. At this early stage, it
is desirable to administer pure drug as an aerosol without ex-
tensive formulation development to establish the feasibility
of inhalation drug delivery. Our approach was to prepare a so-
lution of drug that may be atomized with a nebulizer, after
which the solvent is removed from the aerosol. It then com-
prises pure drug in air with an appropriate particle size
distribution for deposition in the rat lung [37]. The advantage
is that the atomization and drying processes are largely inde-
pendent of the properties of the drug, and thus with the initial
set up, several compounds can be sequentially tested to iden-
tify the optimal in terms of safety and efficacy [38]. Atomization
of liquids readily conforms to a continuous process, which
allows the dose (inhaled and deposited mass) to be adjusted
by the exposure time. In addition, multiple animals may be si-
multaneously exposed.
The compounds for evaluation were all weak bases with rela-
tively low, but quantitatively unknown, pKa’s. The nonionized
forms had very low aqueous solubilities but had good solu-
bility in DMSO; however, removal of DMSO from aerosol droplets
is very difficult, due to its high boiling point/low vapor pres-
sure. The solubility in ethanol was inadequate to generate a
concentrated aerosol of drug. Thus, the approach was to ionize
these compounds with acid such that they would have suffi-
cient solubility in water for nebulization. It was discovered
during the preliminary studies that the pH of the solution would
need to be very low. This in turn raised a concern of toxicity
should such acidic particles deposit in the lung lining. As a
solution, a novel in situ neutralization of the aerosol was used
where aerosol droplets were combined with ammonium vapor.
Following neutralization, the particles were dried. With this ap-
proach, successful administration of the compounds by
inhalation was achieved.
1.14. In situ salt formation in aerosols
For salt preparation in a flowing aerosol, there are two equi-
libria in operation. One is the equilibrium distribution of
ammonia (NH3) between the vapor and liquid, and the other
is the acid/base equilibrium. For the first, the expression is:
NH vapor NH solution3 3( ) ( )
Experimentally, air is initially saturated with ammonia
as it is passed through a bubbler containing ammonium
hydroxide. The vapor concentration may be estimated from
reported values in the literature. It is important to note that
the vapor pressure is a strong function of temperature, so
thermal control of the bubbler is essential.
In the next step, the air with a given concentration of
ammonia is combined with the aerosol. In this step, ammonia
vapor will condense into the liquid droplets in essentially a
reverse process of the bubbler. However, the acid–base chem-
istry within the droplet must be considered. Thus,
NH H O NH OH H3 2 4+ + +
and in the presence of the divalent conjugate acid, BH22+
BH X NH B NH X22 3 42 2 2 2+ − + −+ + + +
where the ammonia is converted to the quaternary ammo-
nium ion by protonation from the acid. With an increase in pH,
the drug is neutralized and may lead to precipitation in the
droplet.
BH X NH NH X B ppt22 3 42 2 2 2+ − + −+ + + + ( )
Alternatively, it may remain kinetically stable in the drop
and precipitate on drying as the salt.
BH X NH BH X ppt NH22 3 2 2 32 2+ −+ + +[ ]( )
2. Materials and methods
2.1. Materials
Compounds I–VI were obtained from the Principal Investiga-
tor per contract through an SBIR grant from NIH.The acids used,
hydrochloric acid, sulfuric acid, mesylic acid, tosylic acid, and
phosphoric acid, and ammonium hydroxide were analytical/
reagent grade.
2.2. Solubility measurements
The solubility of the non-ionized form of compounds I–VI was
determined as follows. For I and II, which were received as HCl
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salts, the material was dissolved in 0.1 M HCl and titrated with
additional concentrated HCl until a solution was obtained. A
volume of sodium hydroxide (ca 24 mM) was added such that
there was an excess of hydroxide ions relative to the esti-
mated hydrogen ions in the sample. A precipitate (free base)
was formed that was washed in a basic solution by alternat-
ing between centrifugation and resuspension. A final rinse of
pH 8 water was used to wash the pellet. The wet pellet was
transferred to 1.5 ml plastic centrifuge tubes and dried. For com-
pounds III–V approximately 10 mg was accurately weighed and
placed into centrifuge tubes with water.The tubes were stored
at room temperature (22 °C) for a minimum of 3 days with
periodic mixing.
After centrifugation, an aliquot was taken, typically 10–20 μl,
and placed into a 1 ml auto sample vial for HPLC. It was diluted
with mobile phase (80/20 methanol/water) and then run on the
HPLC.The HPLC system included a Shimadzu LC-10AT solvent
delivery module, SIL-10AD auto injector, RF-10A XL UV/Vis de-
tector, C-R5A Chromatopac integrator (Shimadzu Corp.,Tokyo,
Japan) and a C18 Agilent column (250 mm × 4 mm, 5 μm) (Agilent
Technologies, Inc. Santa Clara, California). The mobile phase
consisted of 80/20 methanol/water.The UV absorption was mea-
sured at 280 nm. If the resulting peak height fell outside the
standard curve, the solution was further diluted with mobile
phase to yield an appropriate concentration for assay.
HPLC standards were prepared by accurately weighing ap-
proximately 10 mg of the compounds and placing into 25 ml
volumetric flasks. The compound was dissolved in 0.1 M HCl
or DMSO (compounds III and IV). Standard curves were pre-
pared by plotting the observed peak height as a function of
concentration in the standard. Peak areas were also exam-
ined but found to be less reproducible.
The amount of compound in solution in the presence of
various acids was determined as follows. Concentrated acids
were diluted with water to yield an approximate concentra-
tion of 0.1 M assuming the stock concentration was 98% for
H2SO4, 37% for HCl, and the remaining acids were assumed to
be 100%. To centrifuge tubes, 200 μl was added, the dispersion
was vortexed. If a solution was obtained, additional powder
was added.The samples were stored in the refrigerator for 1 day
and then at room temperature for several hours. The samples
were periodically vortexed and then vortexed immediately before
centrifuging. If the volume of the supernatant was insuffi-
cient for taking an aliquot or measuring the pH, more acid was
added. In these cases, the sample was allowed to equilibrate
again. The pH was measured using a micro electrode (Cole-
Parmer, EW-55500-40, 3 mm × 38 mm BNC) that was carefully
inserted into the supernatant of the centrifuge tube.The meter
was unable to measure below a pH of zero, and these are in-
dicated as such.
2.3. Aerosolization, neutralization, and drying
In preparing the solution for the aerosol experiment, 51 mg of
II was weighed and 0.1 M HCl was added to a final weight of
1.995 g. To yield a solution, 0.234 g of concentrated HCl was
added. In this way, a 22.9 mg/g solution of compound II was
obtained. No evidence of decomposition was evident neither
in this solution nor in assaying the compound on the filters
and cascade impactor.
The solution was placed into a PARI nebulizer operated at
a pressure of 12.5 psi, which was the critical pressure for the
maximum flow rate of 1.7 l/min. Air was also directed into a
flask with a bubbler containing 0.3% ammonium hydroxide so-
lution, and the outflow rate was adjusted to 0.3 l/min. These
flows were combined to neutralize the particles, which were
then directed into a drying column.The 3″ (id) Plexiglas column
had a stainless steel mesh fashioned into an annular ring, which
contained silica beads, and an open diameter of 2″ and a 24″
length. At the exit of the column, measurements were made
of the output rate and particle size distribution. For the inha-
lation study in rats, the column was connected to a custom
built, nose-only exposure system [36].
Aerosol exiting the column was collected for a fixed period
of time on filter paper, which was extracted with 0.1 M HCl.
The extract was then assayed by HPLC, and the output rate is
given as mass/time. The aerosol concentration was calcu-
lated by dividing the output rate by the total airflow rate. The
particle size distribution of the aerosol was determined by a
low flow rate cascade impactor (Intox) operating at 0.5 l/min.
Aerosol particles were also collected with Anderson cascade
impactor (filter paper collection affected the pH measure-
ment) and then dissolved in distilled water, and the pH of the
solution was measured.
3. Results and discussion
3.1. Solubility measurements
The results from the measurement of the solubility (mg/ml)
of the free base and the total amount in solution in 0.1 M sul-
furic, mesylic, tosylic, and phosphoric acids are given in Table 2
for the six structurally related compounds. The solubilities of
the nonionized parent bases were very low and in the micro-
gram per milliliter range. With the addition of the different
acids, the total amount of base in solution increased. Sulfu-
ric acid was most effective for increasing the concentration of
compound I and III, and phosphoric acid was most effective
for compounds II, IV, V and VI. However, the effect was rela-
tively modest for III, IV and VI.
Based on the results obtained for the 0.1 M acids, the solu-
bility was measured as a function of acid concentration
using the acid that yielded the highest concentration. The
observed total concentration was plotted as a function of
pH (Fig. 7). The solid lines represent simulations, which
were calculated for the two ionizable groups using the
Table 2 – Concentration (mg/ml) in solution in the
presence of the indicated acid at a concentration of
0.1 M for structurally related compounds, I, II, III, IV, V,
and VI.
I II III IV V VI
Base 0.0013 0.03 0.01 0.0025 0.04 0.08
H2SO4 26. 4.5 0.34 0.49 0.46 0.54
Mesylic acid 6.9 5.3 0.05 0.04 0.20 0.1o6
Tosylic acid 18 2.0 0.09 0.02 43 0.11
H3PO4 2.0 11. 0.30 3.0 240 1.2
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Henderson–Hasselbalch expression. The concentration of the
nonionized free base was taken from Table 2, and it was
assumed that the charged form had an infinite solubility.
Theoretically, the logarithm of the amount of compound in
solution should increase with decreasing pH near the pKa.There
are two evident linear portions in most cases reflecting the pres-
ence of two ionizable groups. In this simulation, the acid
dissociation constants were varied to obtain a good fit based
on the visual appearance. For compound II, the data were well
fit. Those compounds that had lower solubility at low pH than
the simulated values are expected to be limited by solubility
product. Compound V is unusual in that the amount in solu-
tion was much higher than theoretically expected. It is
speculated that self-association may be occurring, which was
not considered in the simulations.
When it became apparent that phosphoric acid could not
be neutralized by ammonium vapor, additional studies of the
solubility as function of acid were carried out. In essence,
the pKa of phosphoric acid is not separated from the pKa of
the drugs by the required two units and thus the captured
aerosol particles remained at a pH of 2.5.
3.2. Aerosol properties
In preliminary neutralization studies, the observed drug output
rate with filter collection was 2.13 ± 0.94 mg/min. The total
output rate of II determined gravimetrically from the change
in mass of the nebulizer was 3.0 mg/min, yielding a column
efficiency of 72%. The mass fraction as a function of cut point
of the cascade impactor is given in Fig. 8. The mass median
aerodynamic diameter was 1.8 μm and the geometric stan-
dard deviation was 1.7.
From the measured pH of the nebulization solution and
output rate of solution (SOPRaer in ml/min), the moles of acid
in unit time in the flowing aerosol were determined. This dic-
tates the moles of ammonia that are required in unit time for
neutralization, which are generated from bubbling air through
a solution of ammonium hydroxide. That is:
H SOPR NH OH k Q
aer aer s H b
+[ ] [ ]∗ = ∗ ∗4
where [H+]aer is the acid concentration in the aerosol drop-
lets, [NH4OH]s is the ammonia concentration in the bubbler,
kH is Henry’s law constant expressed in appropriate units
(moles/liter in air/molar concentration of ammonium), and Qb
is the air flow rate through the bubbler. Data from the litera-
ture of ammonia pressure as a function of weight percent
concentration of [NH4OH]s in solution were plotted and fit to
a quadratic equation:
NH in mole of vapor Liter of air NH OH s3
5
4
22 0 10
2 3 10
( ) [ ]= ×
+ ×
−.
. 4 4NH OH s[ ]
With a solution pH of 2 and a liquid output rate of
150 μl/min, 3 × 10−6 mol/min of acid required neutralization.
Using a concentrated ammonium hydroxide solution diluted
with water at 0.003 g/g, the vapor pressure of ammonia was
calculated to be 0.1 kPa.This is combined with the aerosol drop-
lets at a flow rate of 0.3 l/min, yielding an ammonia production
rate of 1.2 × 10−5 mol/min, which is adequate to neutralize the
aerosol droplets. As the measured values of reconstituted
aerosol particles were between pH 7 and 8, this suggests that
liquid–vapor transfer of ammonia was rapid.
With the output rate and total air flow rate, the aerosol con-
centration was calculated to be 96.1 μg/L [36]. The respiratory
minute volume (RMV) was calculated to be 0.15 l/min based
on animal weight, which leads to a total inhaled dose of 115 μg
for the 8 min exposure. From quantifying the deposited mass
in the rat lung at the end of the exposure, an average of 6.9 μg
was found, which corresponds to a 6% deposition of the inhaled
dose. This is in reasonable agreement, albeit on the low side,
of other inhalation studies in rats using a comparable aerosol
particle size.
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Along with determining the mass of compound deposited
in the lung at the end of the exposure, a pharmacokinetic
study was completed [36]. The lung concentration as a func-
tion of time was fit to a single exponential expression;
C = 2.50 * exp(−0.03t), where the concentration was in μg/g
and the rate constant is given in units of min−1. The corre-
sponding half-life is only 23 min, thus the estimated deposited
mass in the lung has been underestimated as there will be a
non-negligible amount of the compound eliminated from the
lung during the 8 min exposure. Results from assessment of
the safety and efficacy have been reported elsewhere [36].
4. Conclusion
The pH dependence of the amount of six structurally related
compounds was found to be consistent with theoretical ex-
pectations of weak bases.The pH required to achieve the needed
concentration for aerosol generation was low, but ammonia
vapor, introduced into the air stream, effectively neutralized
the aerosol droplets. With solvent removal, the resulting aerosol
was suitable for evaluating the safety and efficacy of inhala-
tion administration in rats.
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